Endocrine treatment in combination with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) is the standard of care in first-line and second-line treatment of advanced hormone-receptor positive human epidermal growth factor receptor 2 (HER-2) negative advanced breast cancer (1, 2). The gene discussed is NR4A1; the disease is breast carcinoma.